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extracranial disease and non-synchronous presentation (HR 
0.51, 95 % CI 0.31–0.82). Patients presenting with poste-
rior fossa metastases may not be investigated as thoroughly 
as those with supratentorial tumours. Staging and assess-
ment is essential however, and in the meantime emergen-
cies related to tumour mass effect should be managed with 
steroids and cerebrospinal fluid diversion as required.
Keywords Brain metastasis · Cerebellar metastasis · 
Posterior fossa metastasis · Neurosurgery
Introduction
Brain metastases (BM) occur in 15–30 % of all ca cers [1 ]. 
They are associated with significant morbidity and have a 
poor prognosis if untreated [2]. Historically the diagnosis of 
brain metastases was considered a pre-terminal event, repre-
senting the end-stage of uncontrollable primary disease and 
treatment was limited to palliative whole brain radiotherapy 
(WBRT) only [3]. The incidence of BM has increased in 
recent years as a consequence of improved imaging, but 
also an effect of improved survival from primary tumours 
[4]. Advances in the management of extracranial disease 
have led to a more aggressive approach in the management 
of brain metastatic disease.
The most common primary site of malignancy for brain 
metastasis is lung (20–40 %) followed by breast (5–17 %) 
and melanoma (7–11 %) with renal, colorectal and gynae-
cological cancers making up the majority of the remaining 
[5–7 ].
There is no curative treatment, even for those patients 
with an apparently isolated metastasis, therefore the aim of 
treatment is extended, quality survival. Previously nihilistic 
management has been superseded by aggressive approaches 
Abstract The diagnosis of brain me astases is as ociate  
with a poor prognosis reflecting uncontrolled primary dis-
ease that has spread to the relative nctuary of the cen ral 
nervous system. 20 % of brain metastases occur in the poste-
rior fossa and are associated with significant morbidity. The 
risk of acute hydrocephalus and poten ial for sudden death 
means these metastases are often alt with as eme gency 
cases. This approach means a full pre-operative assessment 
and staging of underlying disease may be negl cted and 
a proportion of patients undergo comparativ ly high risk 
surgery with little or no survival benefit. This study aimed 
to assess outcomes in patients to identify factors that may 
assist in case selection. We report a retrospective case series 
of 92 consecutive patients operated for posterior fossa 
metastases between 2007 and 2012. Routine demographic 
data was collected plus data on performa ce sta us, pri-
mary cancer site, details of surge y, adjuvant reatment and 
survival. The only independent positive progno tic factors 
identified on multivariate analysis were good performance 
status (if Karnofsky performance score >70, haza d ratio 
(HR) for death 0.36, 95 % confidence interval (CI) 0.18–
0.69), adjuvant whole brain radiother py (HR 0.37, 95 % 
CI 0.21–0.65) and adjuvant chemotherapy wher  there was 
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was overall survival, which was defined as the time from 
diagnosis of brain metastasis to death. Secondary endpoints 
were fitness to receive adjuvant WBRT or systemic chemo-
therapy and surgical complications (infection, return to the-
atre, post-operative hydrocephalus requiring CSF diversion 
within 28 days of resection). Data analysis was performed 
using SPSS (Version 22.0. Armonk, NY: IBM Corp). Uni-
variate time-to-event analyses were performed using the log 
rank test and multivariate analysis by Cox’s proportional 
hazards model.
Results
In total 92 patients were included, 60 female and 32 male, 
with a median age of 59 years (range 37–76). The most 
common primary tumours were lung (33), breast (21), 
colorectal (8) and renal (7). 33 patients (36 %) presented 
synchronously with a solid organ cancer and BM. Of the 59 
patients (64 %) with previously diagnosed primary malig-
nancy (metachronous presentation) 40 (69 %) had stable 
disease and 19 (31 %) had progressive disease (Table 1).
Overall, 74 patients (80 %) underwent gross total resec-
tion (GTR), 13 (14 %) subtotal resection (STR) and 5 (6 %) 
underwent biopsy only. The median interval from diagnosis 
to surgery was 8 days (range: 0–90). Seven patients (7.6 %) 
required pre-operative CSF diversion for acute hydrocepha-
lus. Median overall survival (OS) was 6.00 months (95 % CI 
4.37–7.63). Median Karnofsky Performance Status (KPS) 
as assessed by the clinician at presentation was 80 and 75 % 
of patients had a KPS > 70 [22]. Good performance status 
was associated with longer survival; OS was 7.00 months 
(95 % CI 4.98–9.02) for those with KPS > 70, versus 
2.00 months (95 % CI 0.74–3.26) for those with KPS < 70
(log rank = 21.042, p < 0.001) (Fig. 2a).
Overall, 27 % of operated patients did not go on to 
receive WBRT due to poor performance status and opera-
tive complications. The median time interval from neuro-
surgery to WBRT was 22 days (range 8–64). Receiving 
adjuvant WBRT increased OS significantly; 8.00 months 
(95 % CI 5.90–10.09) if given, versus 2.00 months (95 % CI 
1.12–2.88) if not, log rank test = 17.525, p < 0.001 (Fig. 2b).
Data on adjuvant chemotherapy was available for 85 of 
92 patients of which 41 (48.2 %) went on to receive adjuvant 
chemotherapy for their primary cancer. These patients had 
a 6-month improvement in their median OS compared with 
patients who did not go on to receive chemotherapy from 
3.00 months (95 % CI 2.31–3.69) to 9.00 months (95 % CI 
6.31–11.69) (log rank test = 8.951, p = 0.003) (Fig. 2d).
Median OS for patients presenting with synchronous 
brain metastases was 6 months (95 % CI 4.8–7.2) compared 
to 7 months (95 % CI 2.1–11.8) for those with metachro-
nous presentation, (log rank = 5.297, p = 0.021, Fig. 2c). 
to the control of metastatic disease involvi g both surgical 
resection and stereotactic radiosurgery (SRS). The e are 
associated with appreciable improvem nt in b th progres-
sion-free and overall survival [8–11]. Surgical resection of 
a single large and symptomatic lesion in the p esence of 
additional cranial disease has also been shown to confer a 
survival advantage and symptomatic improvement when 
compared with whole brain radioth rapy (WBRT) alone 
[11, 12]. Stereotactic radiosurgery (SRS), likewise h s been 
shown to confer survival adv ntage an  the addition of 
WBRT improves local disease control, although it does not 
appear to increase overall survival [13–15].
Improved imaging modalities, par icularly the routine 
use of contrast-enhanced MRI, have allowed us to gain a 
more accurate impression of the disease burden and this has 
resulted in a decreased incidence of solit ry metast tic dis-
ease, with 50–75 % of patients now presenting with multiple 
lesions [16, 17].
The posterior fossa is an important site for BM with 20 % 
of lesions observed to occur her  in historical eries [18]. 
BMs in this region exerting mass effect prese t with  char-
acteristic triad of symptoms consisting of headache, ataxi  
and nausea/vomiting. Neurosurg ons and oncologists a e 
wary of posterior fossa BMs in particular due to the risk 
of acute obstructive hydrocephalus with rapid coma and 
death if this not managed expediently [19]. As a re ult, there 
has been a trend to manage these cas s as emergencies by 
resecting the tumour. This may be preceded or as ociated 
with CSF diversion, particularly in those patients who p es-
ent with a rapid deterioration out of hours [20, 21]. Th s 
expedited approach to surgery of en comes at the expense 
of a full pre-operative work up includ ng a staging CT scan 
(chest, abdomen and pelvis) and informati n about lik ly 
prognosis and options for systemic treatment. See illustra-
tive cases in Fig. 1. The aim of this study was to assess the 
outcome of surgery in patients with posterior fossa brain 
metastases in a single centre in order to id ntify factors that 
may assist in case selection in future.
Materials and methods
Patients who underwent posterior fossa surgery for meta-
static tumours between 2007 and 2012 were identified from 
a computerised operative database (MD analyse v3.11). 
The institution is a regional neurosc ences c re serving a 
population of approximately 3.5 million. Demographic a d 
clinical information was collected from operative otes, 
pathology reports, clinical case notes, correspondence, 
radiological images and HES mortality data. Only adult 
patients (16 years+) were included fo  study. Subjects were 
stratified by good performance status defined by convention 
as KPS > 70, the ability to self-care. The primary endpoint 
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Variables that did not have a statistically significant bear-
ing on prognosis included sex, age > 65 years, multipl  
cranial lesions, extracranial disease and control of primary 
cancer. RPA class similarly did not appear to have a signifi-
cant influence on median OS (Table 1).
Multivariate analysis using Cox proportional hazards 
model suggested that good performance status (KPS > 70), 
45 patients presented with either ynchronou  pr mary and 
metastatic disease, or with metachronous prese tation with 
progressive primary disease. D ta was available for 39 of 
these patients and showed th t 22 (56 %) were considered 
unfit for systemic chemotherapy due to poor performance 
status. Six of these patients (15.4 %) were too unfit for 
WBRT when assessed by oncologists after surgery.
Fig. 1 Illustrative cases. Case 1 images (a) and (b) 54 year old 
female. PMH Breast cancer (Her2 positive) Treated with mastectomy 
1 year ago plus adjuvant chemotherapy (trastuzumab). Presented 
with 2 weeks of headaches and unsteadiness. CT brain revealed (a) 
large solid left cerebellar tumour, confirmed on MRI (b). KPS 90 
pre-operatively. CT staging pre-op showed local lymph node involve-
ment but no other metastatic disease. Underwent craniotomy and 
gross total resection with adjuvant WBRT and further systemic che-
motherapy. Re-presented with similar symptoms 21 mon s later and 
MRI showed recurrent tumour at the same site. CT staging showed 
no evidence of extracranial disease. Further craniotomy and gross 
total resection performed. No further adjuvant therapy given. Gradual 
deterioration 10 months after second surgery and died 36 months after 
initial diagnosis. Case 2 images (c) and (d) 67 year old male. PMH
T ticular cancer - orchidectomy 12 years ago. Presented with increas-
ing confusion, headache, unsteadiness and falls. Acute deterioration 
the previous day. KPS 50 on arrival. CT head revealed 36 × 25 mm 
left c rebellar haemorrhagic tumour with triventricular hydrocephalus 
(c). Transferred to regional neurosurgical unit and external ventricu-
lar drain (EVD) inserted. MRI confir ed solitary bulky left cerebel-
l r (d). Gross total resection performed later that admission, histology 
revealed metas atic carcinoma. Post- operatively the patient developed 
bulb r dysfunction and swallowing difficulty. Staging CT performed 
post-operatively revealed metastatic lung cancer with mediastinal and 
liver metastases. EVD reinserted due to post-operative hydrocephalus. 
5 days of p lliative WBRT administered as an inpatient. Continued 




Table 1 Data for 92 patients surgically treated for posterior fossa metastases




Variable Classification Number %






Classification Number % Median OS—months 
(95 %CI)







<65 67 72.8 7.00 (5.42–8.58) 3.781 (0.052)
>65 25 27.2 4.00 (2.12–5.88)
Gender
M 32 34.8 5.00 (4.12–7.88) 3.276 (0.07)
F 60 65.2 6.00 (2.84–7.15)
Adjuvant radiotherapy
Y 63 73.3 8.00 (5.9-10.09) 17.525 (<0.001)* 0.001* 0.374 
(0.213–0.654)
N 23 26.7 2.00 (1.12–2.88)
Adjuvant chemotherapy
Y 41 48.2 9.00 (6.31–11.69) 8.951 (0.003)* 0.006* 0.507 
(0.314-0820)
N 44 51.8 3.00 (2.31–3.69)
Number of cranial metastases
Single 73 79.3 6.00 (4.36–7.64) 0.371 (0.54)
Multiple 19 20.7 5.00 (1.59–8.41)
Karnofsky performance status
>70 68 74.7 7.00 (4.08–9.02) 21.042 (<0.001)* 0.002* 0.356 
(0.184–0.689)
<70 23 25.3 2.00 (0.74–3.26)
Synchronous presentation
Y 33 36.3 6.00 (4.80–7.20) 5.297 (0.021)* 0.164 1.423 
(0.866–2.338)
N 58 63.7 7.00 (0.89–13.11)
Extracranial metastases
Y 50 54.9 6.00 (2.91–9.09) 0.096 (0.756)
N 41 45.1 6.00 (4.87–7.13)
Primary disease status
Stable 40 69 7.00 (0.89–13.11) 0.001 (0.973)
Progressive 18 31 6.00 (2.15–11.85)
RPA class
I 22 23.9 5.00 (3.10-10.91) 2.656 (0.265)
II 64 69.6 6.00 (4.79–7.63)
III 5 5.4 4.00 (0.53–7.42)
Asterisk denotes statistical significance p < 0.05
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The 28 day mortality was 7.6 % (n = 7) with a periop-
erative morbidity of 22.8 % (n =21). These included 6 deep 
wound infections; 5 abscesses requiring re-operation and 1 
episode of ventriculitis. There were 14 cases of post-opera-
tive hydrocephalus, half of which required permanent CSF 
diversion (5 VP shunt, 1 Ommaya reservoir and 3 endo-
scopic third ventriculostomy).
progression to adjuvant WBRT and chemother py were 
independently associated with a good outcome, HR for 
death 0.36 (95 % CI 0.18–0.69), 0.37 (95 % CI 0.21–0.65) 
and 0.51 (95 % CI 0.31–0.82) respectively. Synchronous 
presentation was not independently ass ciated with overall 
survival based on multivariate analysis, HR 0.16 (95 % CI 
0.86–2.34) (Table 1).
Fig. 2 a Kaplan–Meier survival analysis for patients with good 
Karnofsky performance status (>70) versus those with poor (<70) 
(log rank = 21.042, p < 0.001). b Kaplan–Meier survival analysis for 
patients receiving adjuvant WBRT versus those who did not receive 
WBRT. (log rank test = 17.525, p < 0.001). c Kaplan–Meier survival 
analysis for synchronous versus metachronous presentation. (log rank 
t st = 5.97, p = 0.021). d Kaplan–Meier survival analysis comparing 
patie ts who received adjuvant chemotherapy for synchronous or 
uncontrolled systemic disease versus patients who did not receive this 




proven to be an accurate prognostic indicator when consid-
ering supratentorial disease, showed no correlation with sur-
vival in our series. Furthermore, comparison of survival of 
posterior fossa BM patients with a series of supratentorial 
BM patients from the same unit and time period revealed 
poorer prognosis for patients with infratentorial disease 
even when matched for KPS and progression to adjuvant 
therapy (WBRT and chemotherapy).
Initial series of cerebellar tumour resections performed in 
the late nineteenth century had mortality rates of up to 70 %. 
These improved from the 1920s to 20 % with impr ve-
ments in surgical technique, anatomical understanding and 
perioperative care [19]. The development of microsurgi-
cal techniques in the last 50 years has resulted in a further 
improvement in operative mortality. Postoperative CSF leak 
is of particular concern due to the risk of deep infection and 
meningoencephalitis and ventriculitis. Most commonly, this 
is a result of altered CSF flow dynamics and post-opera-
tive hydrocephalus. Patients frequently require further CSF 
diversion procedures to manage this, extending hospital 
stay and further increasing the surgical stress on the patient. 
Shunt procedures are themselves associated with infection 
risk and risk of revision within 30 days may be as high as 
13 % in some series [30]. In addition, shunt systems may 
block, particularly in the presence of blood and high CSF 
protein associated with metastatic disease.
Endoscopic third ventriculostomy (ETV) presents an 
attractive treatment option to treat obstructive hydrocepha-
lus avoiding complications associating with VP shunts. The 
literature for ETV in metastatic disease is limited, its use 
is mainly established for paediatric posterior fossa tumours 
and benign aqueduct stenosis in adults [31, 32]. Success 
rates of shunt independence are quoted between 50 and 
90 % for all indications, with most series reporting suc-
cess rates of around 70 % [33–38]. In our series 3 ETVs 
were performed, 2 of which failed requiring subsequent VP 
shunt. High CSF protein and haemorrhage from metastatic 
tumours are proposed as the mechanism predisposing occlu-
sion of ventriculostomy in this population.
Interpretation of our data is limited by the study’s retro-
spective design, nevertheless this represents an unselected 
series of patients operated for posterior fossa metastases. 
The improved survival associated with progression to adju-
vant therapy may reflect a surrogate effect due to these 
patients having a better baseline performance status. Future 
prospective studies would be of use to guide treatment, spe-
cifically to further delineate those factors that accurately 
predict improved survival. Likewise, further information on 
why patients with infratentorial tumours do worse than their 
supratentorial counterparts would assist in the selection of 
patients who are likely to benefit from surgical intervention. 
In the acute setting, even limited information about sys-
temic disease status would help in selection those patients 
Fewer patients with post-ope ative complications (62 %)
went on to receive WBRT compared to those with ut com-
plications (70 %). There was no significant delay in the time 
from surgery to receiving WBRT between these groups 
(Student t test, p = 0.206).
Furthermore, comparison of survival f posterior fossa 
BM patients with a series of supratentorial BM patients from 
the same unit and time period revealed poorer prognosis for 
patients with infratentorial d se se ven when matched for 
KPS and progression to adjuvant therapy (WBRT a d ch -
motherapy). On univariate analysis posterior f ssa locati n 
showed a non-significant trend towards negative prognosis, 
median OS 6.1 months (95 % CI 4.5–7.8) versus 9.3 months 
(95 % CI 6.0–12.6) for patients with supratentorial metas-
tases (log rank = 1.219 p = 0.270). Multivariate analysis
including performance status (KPS > 70) and progre sion 
to adjuvant therapy using Cox proportional hazards mod l 
however revealed a significant negative prognostic effect 
of posterior fossa location, HR 1.43 (95 % CI 1.04–1.98) 
p = 0.029.
Discussion
Our single centre series of 92 cases has shown that patients 
with posterior fossa BM have a poor prognosis, with median 
OS of 6 months. Factors associate  with a longer survival 
were KPS > 70 at presentation and prog ess on o adjuvant 
WBRT and systemic chemotherapy for uncontr lled extra-
cranial disease.
Despite the growing arsenal of treatments for systemic 
cancer, the management of br in metas ases ha  remained 
largely unchanged for over 20 y ar . Chemotherapy for BM 
is of limited utility due to the poor penetrance of pharma-
cological agents into the central nervous system. Treatment 
therefore consists for the most part f surgical r section of 
the visible lesion or lesions i  ol ometastat c cases fol-
lowed by fractionated WBRT or SRS.
SRS presents an appealing treatment option for poste-
rior fossa metastases but concerns regarding its safe y exist. 
Following treatment, tumours and peritumoural tissue can 
swell and exert mass effect on surrounding structu es [23–
25]. This precludes the use of SRS in those patients with 
a crowded posterior fossa and established or imp nding 
hydrocephalus.
A previous case series published in 2003 found surviva  
with posterior fossa metastases to be compar ble o that of 
patients with supratentorial metastases when the groups 
were stratified by RPA class [26]. This runs counter to a 
number of other case series which found worse prognosis 
associated with infratentorial locatio  [20, 27–29]. Ou  
series demonstrates a median OS of 6 month  for all op r-
ated posterior fossa BMs. Grouping patients by RPA class, 
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that would benefit from direct surgical resection of a poste-
rior fossa metastasis, for example, known breast cancer with 
good performance status. This contrasts with the patient 
with widespread metastatic dis ase and poor performance 
status in whom CSF diversion may be ore appropr ate to 
determine whether they will benefit from surgical resection 
and adjuvant therapy.
Conclusions
We present a retrospective single-unit cas  series of 92 
patients undergoing surgery for p sterior fossa meta tases 
further confirming the dismal prognosis associated with this 
diagnosis. Good performance st tus (KPS > 70) and pro-
gression to receive adjuvant WBRT and/or chemotherapy 
were the only independently significant prognostic factors. 
In view of the high morbidity and mortality associated with 
surgical resection, we propose that these patients should be 
managed with corticosteroids a d temporary CSF diver-
sion if required in the first instance rather than proceeding 
to emergency surgical resection wherever possible. This 
allows sufficient time to complete a full pre-operative work-
up of all patients prior to surg ry inclu ng cancer staging. 
In doing this it should be possible to identify those patients 
who will benefit from surgery and spare those who will not 
the associated operative morbidity.
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